LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

LIGAND PHARMACEUTICALS INCORPORATED Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $44.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-27

• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $44.60M, a 15.54% increase from fiscal 2024.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $38.60M, a 221.67% increase from fiscal 2023.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $12.00M, a 160.87% increase from fiscal 2022.
• LIGAND PHARMACEUTICALS INCORPORATED share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $4.60M.